Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen for Breakthrough Bleeding in ENG Implant Users
NCT02903121Phase 4Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tamoxifen in breakthrough bleeding, sponsored by Oregon Health & Science University. Primary endpoint: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment. Started Jan 2017; status: completed.
02
Drugs
tamoxifen
03
Conditions
breakthrough bleeding
Beyond the preview
Go deeper on NCT02903121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903121.